Cancer Risks From Exposures to Radiation

Slide 1 · Cancer Risks From Exposures to Radiation

Molecular mechanisms, human evidence, and clinical risk interpretation

Ionizing exposure

DNA damage

Surviving mutated cell

Delayed cancer

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Trace ionizing radiation from DNA injury to delayed malignant transformation.

Interpret evidence at high doses and uncertainty at lower exposures.

Identify cancer patterns after fallout, radiotherapy, imaging, and radon.

Explain why pediatric exposure and exposure context influence risk.

Slide 3 · Radiation-associated cancer is a delayed outcome

Ionizing radiation can produce mutations in cells that remain viable and capable of division.

Such cells can contribute to neoplastic transformation long after the exposure.

Population studies demonstrate excess leukemias and solid tumors after major exposures.

Immediate tissue injury and late cancer development are distinct outcomes.

Slide 4 · A viable mutated cell creates the biological possibility

Ionizing exposure

DNA alteration

Cell survives

Altered progeny

Potential neoplasm

Mutation is necessary for this pathway, but exposure does not make every altered cell malignant.

Slide 5 · Radiation can injure DNA directly

Ionization can disrupt atoms and molecular bonds within cellular material.

DNA lesions include base damage, strand breaks, and DNA–protein crosslinks.

The biological effect depends on the damage and the cellular response.

An unrepaired lesion is not equivalent to a fixed mutation unless the cell survives and propagates it.

Slide 6 · Water radiolysis generates reactive intermediates

Ionizing radiation

Water radiolysis

Free radicals / ROS

DNA injury

Indirect radical-mediated injury is a major mechanism of radiation-induced DNA damage.

Slide 7 · DNA lesions differ in their consequences

Lesion

Why it matters

Single-base damage

May be corrected by cellular DNA repair systems.

Single-strand break

Often repairable; contributes to the damage burden.

Double-strand break

Especially serious; joining errors can alter chromosomes.

DNA–protein crosslink

Interferes with normal DNA structure and processing.

Slide 8 · Double-strand breaks are particularly consequential

They disrupt both strands of the DNA double helix.

Surviving cells require a mechanism to restore chromosomal continuity.

Faulty repair may cause deletions, duplications, inversions, or translocations.

The resulting chromosomal damage can persist when cell-cycle controls fail.

Slide 9 · Two routes repair double-strand breaks

Homologous recombination

One of two major mammalian double-strand break repair pathways.

Uses homologous sequence information to guide repair.

Nonhomologous end joining

as the more common DSB repair pathway.

End joining can introduce sequence changes or rearrangements.

Slide 10 · End joining may restore continuity with a genomic cost

Broken DNA ends

End joining

Imperfect junction

Persistent mutation

Physical restoration of a chromosome does not guarantee preservation of its original sequence.

Slide 11 · Chromosomal rearrangements may persist after repair

Inversions change the orientation of a chromosomal segment.

Translocations move material between chromosomal locations.

Short deletions or duplications can modify genomic content.

These outcomes among mutations associated with NHEJ.

Slide 12 · Cell-cycle checkpoints provide a crucial safeguard

DNA breaks

Checkpoint response

Repair / arrest

Safe recovery or loss

If bypassed: Persistence

A damaged cell becomes a lasting hazard when altered genetic material survives checkpoint control.

Slide 13 · Cancer risk extends beyond the exposure event

Damage arises during irradiation; Malignant transformation need not be immediate.

Persisting chromosomal abnormalities can contribute to carcinogenesis years later.

Additional transforming events may follow the initial genetic lesion.

Clinical latency therefore does not exclude an earlier radiation contribution.

Slide 14 · Tissue destruction and carcinogenesis are not the same

Early tissue injury

Cell loss follows DNA damage and impaired replication.

Often conspicuous in rapidly proliferating normal tissue.

Late cancer risk

Requires surviving cells with retained or acquired oncogenic changes.

May emerge after a prolonged interval without obvious acute injury.

Slide 15 · A plausible mechanism is not a patient-level diagnosis

Radiation is a demonstrated human carcinogen in the settings discussed by Robbins.

A specific tumor cannot automatically be assigned to a particular exposure.

Interpretation requires exposure history, latency, organ involved, and population evidence.

A cancer diagnosis alone does not reveal its etiologic origin.

Slide 16 · Biological effects depend on exposure context

Modifier

Biologic relevance

Dose delivery

Intervals may allow cellular repair.

Field size

Changes the volume and organs exposed.

Cell proliferation

Actively dividing populations are vulnerable to DNA injury.

Oxygenation

Influences free-radical-mediated injury.

Vascular response

Can drive fibrosis and chronic ischemic tissue change.

Slide 17 · Spacing radiation doses changes repair opportunity

Dose fraction

Recovery interval

Partial DNA repair

Next exposure

Fractionation modifies biological damage; It does not erase all accumulated exposure effects.

Slide 18 · Field size determines the exposed tissue population

Localized field

Only a restricted anatomical region is deliberately irradiated.

Tissues outside the field may be shielded.

Broad exposure

More organs and proliferating cell populations receive energy.

Consequences can differ even if a simple dose number looks similar.

Slide 19 · Oxygen participates in radical-mediated injury

Water-derived radicals

Oxygen-dependent chemistry

Reactive oxygen species

Increased DNA injury

This describes a determinant of biological effect, not a patient-specific numerical cancer-risk estimate.

Slide 20 · Fibrosis is a separate late radiation complication

Vascular pathway

Endothelial damage may produce luminal narrowing or occlusion.

Chronic ischemia impairs tissue function and healing.

Cancer pathway

Surviving genetically altered cells can continue dividing.

Neoplastic transformation may develop after years.

Slide 21 · Absorbed dose and biologic dose answer different questions

Measure

Meaning

Gray (Gy)

Energy absorbed per unit tissue mass.

Sievert (Sv)

Dose measure weighted for biological effect.

Millisievert (mSv)

One-thousandth of a sievert; used for small exposure summaries.

Interpretation

A single dose figure is insufficient to specify individual cancer outcome.

Slide 22 · An mSv value requires careful interpretation

The number summarizes an exposure estimate rather than a cancer diagnosis.

Type of radiation, anatomical distribution, and exposure context still matter.

Radiological risk discussions should distinguish absorbed from weighted dose.

Comparisons are most defensible when measures refer to the same dose quantity.

Slide 23 · Radiation-associated cancer is a probability question

The endpoint of concern is a change in future cancer incidence.

An exposed group can show excess cancers without every individual becoming ill.

An unexposed person may develop the same tumor type for unrelated reasons.

Population evidence and individual attribution are different inferential tasks.

Slide 24 · Higher-dose exposure has established carcinogenic consequences

Exposures producing doses greater than 100 mSv as clearly concerning.

Major human exposure settings show later leukemias and solid tumors.

The existence of excess cancer is well supported; Precise risk varies with exposure circumstances.

This statement is not a claim that doses below 100 mSv are safe.

Slide 25 · The 5–100 mSv range creates a detection problem

Expected increases in cancer incidence may be small relative to background incidence.

Dose reconstruction may not be precise in every exposed individual.

Substantial difficulty measuring the long-term risk in this interval.

Uncertain estimation must not be interpreted as absence of biological effect.

Slide 26 · Do not turn epidemiologic dose ranges into thresholds

Levels of statistical evidence, not a biologically established safe cutoff.

Different populations and designs can yield different statistical precision.

A measured association is not identical to a universal minimum carcinogenic dose.

Use the word “evidence” rather than “no risk below” when teaching low-dose effects.

Slide 27 · Acute x-ray and gamma-ray evidence above 50 mSv

Good evidence for a statistically significant excess risk at acute doses greater than 50 mSv.

This statement concerns population-level cancer incidence.

The radiation type and acute-exposure context are material qualifiers.

It should not be generalized automatically to every organ or delivery pattern.

Slide 28 · Very low acute doses: Evidence is less certain

“reasonable evidence” at acute x-ray and gamma-ray doses greater than 5 mSv.

Low-dose risk estimates require careful interpretation of uncertainty.

The textbook does not give an individual probability of malignancy for a single low-dose examination.

Do not invent a numerical probability from an exposure value alone.

Slide 29 · Small excess risks require large study populations

Common background cancers

Small added effect

Weak signal-to-noise

Large cohorts needed

That studies may require roughly 50,000–5,000,000 participants to quantify risk in the 5–100 mSv range.

Slide 30 · Population associations are not causal labels for each tumor

An exposed cohort supplies information about frequency, not a unique signature in an individual cancer.

The same tumor type occurs through multiple carcinogenic pathways.

Causation is assessed with exposure details and cumulative evidence.

Use “radiation-associated” when attribution in a single patient is uncertain.

Slide 31 · Radiologic exposure estimates are context dependent

Reported dose examples are illustrative, not values for every machine or protocol.

Anatomical target and exposure geometry differ between radiography and CT.

A contemporary clinical estimate requires the particular examination and setting.

Robbins values are retained here as textbook-era reference examples only.

Slide 32 · Chest imaging: Examples reported by Robbins

Examination

Reported dose

Posteroanterior chest radiograph

0.01 mSv

Lateral chest radiograph

0.15 mSv

Chest CT

10 mSv

Values quoted from the textbook as lung-related effective-dose examples; Not universal current protocol estimates.

Slide 33 · A dose estimate is not a cancer-risk calculation

Examination

Exposure estimate

Biological modifiers

Population evidence

Risk interpretation

Avoid translating “one CT” directly into a fabricated individual cancer percentage.

Slide 34 · Evidence settings described

Exposure setting

Reported tumor signal

Atomic-bomb survivors

Leukemias and solid tumors in several organs.

Chernobyl nuclear accident

Increased thyroid cancers.

Marshall Islands fallout

Thyroid tumors and elevated leukemia frequency.

Therapeutic irradiation

Second hematologic and solid malignancies.

Radon exposure

Lung cancer risk.

Slide 35 · Hiroshima and Nagasaki: A foundational observation

Atomic-bomb survivors

EXPOSURE

Major ionizing radiation exposure

OBSERVED FINDING

Increased leukemias and several solid tumors

INTERPRETATION

Supports human carcinogenicity across different tissue types.

Slide 36 · Atomic-bomb survivors: Example tumor spectrum

Malignancy group

Example reported by Robbins

Hematologic

Leukemias

Endocrine

Thyroid tumors

Breast

Breast cancers

Respiratory

Lung cancers

Slide 37 · Leukemia is one observed radiation-associated malignancy

An increased incidence of leukemia is documented among atomic-bomb survivors.

The Marshall Islands account also reports elevated leukemia frequency.

Radiotherapy survivors may develop acute myeloid leukemia.

These observations come from different exposure contexts and should not be pooled as one dose-response estimate.

Slide 38 · Radiation-associated solid tumors involve multiple organs

Thyroid, breast, and lung tumors among atomic-bomb survivor outcomes.

Tumor distribution depends on which tissues were exposed and the exposure setting.

An observed association does not imply every tissue has equal sensitivity.

Organ-specific evidence is more informative than a universal “cancer risk” label.

Slide 39 · Chernobyl: Thyroid cancer after a nuclear accident

Chernobyl accident

EXPOSURE

Population exposure following reactor accident

OBSERVED FINDING

Increased thyroid cancers among survivors

INTERPRETATION

A radiation-associated tumor pattern can be prominent in a particular organ.

Slide 40 · Marshall Islands: Cancer risk after nuclear fallout

Marshall Islands inhabitants

EXPOSURE

Exposure to nuclear fallout

OBSERVED FINDING

Thyroid tumors and elevated leukemia frequency

INTERPRETATION

The textbook also mentions birth defects, a distinct non-cancer outcome.

Slide 41 · Exposure route and anatomy influence observed outcomes

Exposure description

External whole-body or regional irradiation differs from internal exposure.

The responsible radionuclide or radiation type can matter.

Outcome interpretation

Assess organs receiving the biologically relevant exposure.

Keep tumor outcomes separate from other radiation injury.

Slide 42 · Radiotherapy raises a long-term survivorship question

Cancer-treatment survivors

EXPOSURE

Radiation therapy for a prior malignancy

OBSERVED FINDING

Subsequent myeloid and solid malignancies

INTERPRETATION

The immediate therapeutic aim and later carcinogenic hazard must be considered separately.

Slide 43 · Acute myeloid leukemia and MDS are reported late effects

Acute myeloid leukemia among secondary cancers after radiotherapy.

Myelodysplastic syndrome is also explicitly listed.

These entities represent distinct marrow disorders following cancer treatment.

A specific therapy-related diagnosis requires the individual clinical and pathological context.

Slide 44 · Solid second cancers can follow regional irradiation

Solid tumors as another delayed neoplastic consequence of radiotherapy.

The exposure field provides anatomical context for evaluating later lesions.

A new solid tumor is not automatically recurrence of the original malignancy.

Long-term follow-up must be interpreted without assuming causation for every new tumor.

Slide 45 · Therapeutic benefit and late risk coexist

Immediate treatment objective

Deliver a tumoricidal radiation dose to the cancer.

Exploit differences in damage recovery between tumor and normal tissue.

Delayed complication

Normal surviving cells may retain radiation-associated genomic changes.

Secondary malignancy risk enters long-term survivorship assessment.

Slide 46 · Acute injury and secondary cancer require different timelines

Feature

Acute injury

Second malignancy

Principal process

Direct tissue damage and cell loss

Survival and propagation of altered cells

Clinical pattern

Early dysfunction in sensitive tissues

New cancer after a long interval

Biologic endpoint

Tissue depletion or inflammation

Clonal neoplastic proliferation

Slide 47 · Pediatric exposure requires special attention

Children a group with particularly high secondary-cancer concern.

Exposure occurs while many tissue cell populations remain proliferative.

Long intervals after childhood exposure permit late outcomes to become clinically apparent.

The practical interpretation still depends on actual exposure and clinical need.

Slide 48 · Repeated pediatric CT: Small measured associations

Pediatric CT epidemiology

EXPOSURE

Children receiving at least two CT examinations

OBSERVED FINDING

Very small but measurable increases in leukemia and malignant brain tumors

INTERPRETATION

A measurable population association does not imply a large absolute risk for an individual child.

Slide 49 · Relative and absolute increases answer different questions

Relative change

Compares incidence between groups.

Can appear important even when the baseline event is uncommon.

Absolute change

Counts added events over a defined population and period.

Is necessary for balanced communication of a “very small” increase.

Slide 50 · Adolescent chest irradiation: Later breast cancer

Historical radiotherapy cohorts

EXPOSURE

Chest irradiation during adolescence

OBSERVED FINDING

Increased subsequent breast cancer in females exposed at that age

INTERPRETATION

Age at the time of exposure can matter for the later tumor spectrum.

Slide 51 · Timing of exposure changes the reasoning problem

Childhood / adolescence

Different developmental and proliferative tissue context.

Potential for extended follow-up after exposure.

Later-life exposure

Different tissue state and competing clinical risks.

Do not assume identical risk at the same reported dose.

Slide 52 · Radon originates in the natural decay of uranium

Uranium decay

Radon gas

Radon decay products

Alpha emissions

Polonium-214 and polonium-218 as carcinogenic radon progeny.

Slide 53 · Radon progeny cause localized alpha exposure

Inhaled radon

Polonium-214 / -218

Deposition in lung

Alpha-particle injury

The carcinogenic exposure arises largely from alpha-emitting daughters rather than a generic “radon dose.”

Slide 54 · Lung localization explains the primary tumor outcome

Airborne exposure

Inhalation

Lung deposition

Repeated local exposure

Lung carcinoma risk

The causal chain links environmental exposure to the tissue in which cancer is observed.

Slide 55 · Uranium miners: Occupational lung-cancer risk

Uranium-mining exposure

EXPOSURE

Chronic inhalation of radon decay products

OBSERVED FINDING

Elevated risk of lung carcinoma

INTERPRETATION

A prolonged workplace exposure can produce a recognizable organ-specific malignancy.

Slide 56 · Residential radon can also present a carcinogenic hazard

Cancer risk in homes with very high radon levels.

Some household concentrations can approach levels found in mines.

Lower residential concentrations are described as suspected contributors to lung cancer.

A household address does not substitute for an actual exposure assessment.

Slide 57 · Radon and tobacco require combined risk thinking

Radon

Alpha-emitting daughter products expose pulmonary tissues.

Lung carcinoma is the reported associated malignancy.

Tobacco co-exposure

Particular concern among people who smoke.

The excerpt does not quantify interaction or supply a joint risk ratio.

Slide 58 · Textbook mortality estimates are time-bound

Nearly 3,000 annual U.S. Nonsmoker deaths to radon, citing a CDC estimate.

This is a reported textbook figure, not independently verified current surveillance.

It highlights public-health importance without resolving individual cancer attribution.

Do not present the figure as an up-to-date count without checking its original source and year.

Slide 59 · Risk interpretation requires more than knowing a hazard

Hazard identified

Actual exposure

Tissue dose

Epidemiologic evidence

Clinical judgment

The same carcinogenic agent can be associated with different risk profiles across exposure settings.

Slide 60 · A radiation-risk study needs interpretable inputs

Question

Why it affects inference

Which population?

Baseline disease frequency and age may differ.

What exposure?

Radiation type, intensity, dose and distribution matter.

How measured?

Dose misclassification can obscure small effects.

What outcome?

Leukemia and organ-specific solid tumors are distinct endpoints.

What follow-up?

Malignancies may appear long after exposure.

Slide 61 · Exposure settings: Compare before generalizing

Setting

Exposure structure

Cancer signal

Bombings

Acute population exposure

Leukemias and several solid cancers

Fallout

Environmental contamination

Prominent thyroid and hematologic outcomes

Radiotherapy

Targeted therapeutic fields

Late hematologic and solid second cancers

CT imaging

Medical diagnostic exposures

Small epidemiologic signals in childhood

Radon

Chronic inhalational exposure

Lung carcinoma

Slide 62 · Low-dose interpretation should preserve uncertainty

Lower-dose cancer risk as difficult to measure rather than absent.

Population size, exposure reconstruction, and tumour background rates limit statistical certainty.

Numeric estimates for a particular patient cannot be extracted from the textbook’s dose examples.

Clinically necessary irradiation and avoidable exposure should not be discussed as identical decisions.

Slide 63 · Case reasoning: Cancer years after Hodgkin radiotherapy

A long-term survivor of Hodgkin lymphoma develops a new myeloid malignancy. Which exposure history is relevant?

Reasoning checkpoints

Prior therapeutic irradiation is relevant to secondary malignancy assessment.

AML and MDS are listed by Robbins among post-radiotherapy neoplastic outcomes.

The diagnosis still requires clinical and pathological evaluation.

Slide 64 · Case reasoning: Repeated childhood CT examinations

A child underwent multiple CT examinations. How should possible later cancer risk be explained?

Reasoning checkpoints

A very small measurable association for leukemia and malignant brain tumors after at least two CT scans.

Avoid translating scan count into a fabricated individual probability.

Explain the evidence while preserving the medical context of the examinations.

Slide 65 · Case reasoning: Residential radon and smoking

A person who smokes is concerned about radon exposure at home. What is the relevant malignant endpoint?

Reasoning checkpoints

Radon daughter products can deposit in lung and emit alpha particles.

Lung carcinoma is the important radiation-related cancer in the excerpt.

Smoking co-exposure heightens concern, but no interaction ratio is provided.

Slide 66 · A common causal framework links all exposure settings

Source / route

Ionizing energy

DNA breaks

Aberrant persistence

Potential cancer

Epidemiologic evidence is required to establish how often the late outcome occurs.

Slide 67 · Five conclusions for clinical interpretation

Ionizing radiation is a proven human carcinogen.

Unrepaired or aberrantly repaired DNA damage creates a plausible transformation pathway.

Strong evidence comes from bombings, nuclear fallout, radiotherapy, and radon.

Children and irradiated survivors warrant special attention in long-term assessment.

Low-dose uncertainty is not proof of zero risk, and dose alone is not an individual prognosis.

Slide 68 · Principal source and scope

Robbins, Cotran & Kumar: Pathologic Basis of Disease. 11th ed. (2026).

Primary teaching section: Cancer Risks From Exposures to Radiation.

Mechanistic context: DNA Damage and Carcinogenesis; Main Determinants of Biologic Effects of Ionizing Radiation; Radiation Units.

No independent update to imaging-dose estimates or historical surveillance figures is claimed.